Stabilizing Gold Nanoparticle Bioconjugates in Physiological Conditions by PEGylation

  • Joan Comenge
  • Víctor F. Puntes
Part of the Methods in Molecular Biology book series (MIMB, volume 1025)


Stability of gold nanoparticles (AuNPs) is often compromised in physiological conditions. The loss of colloidal stability might lead to undesired biological responses for drug delivery nanosystems. Here a methodology to confer additional stability to the AuNPs by the addition of PEG is presented. Also, protocols to prepare and characterize the composition and conformation of mixed layers with PEG and alkanethiols are described here. Finally, methods to assay the stability of the link between the NP conjugates and a model drug are shown.

Key words

Gold nanoparticles Conjugates Biological stability PEG Mixed layers Protein corona Link stability Cisplatin 


  1. 1.
    Daniel MC, Astruc D (2004) Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 104:293–346CrossRefGoogle Scholar
  2. 2.
    Rana S, Bajaj A, Mout R, Rotello VM (2012) Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 64:200–216CrossRefGoogle Scholar
  3. 3.
    Ruenraroengsak P, Cook JM, Florence AT (2010) Nanosystem drug targeting: facing up to complex realities. J Control Release 141:265–276CrossRefGoogle Scholar
  4. 4.
    Lim IS, Goroleski F, Mott D, Kariuki N, Ip W et al (2006) Adsorption of cyanine dyes on gold nanoparticles and formation of J-aggregates in the nanoparticle assembly. J Phys Chem B 110:6673–6682CrossRefGoogle Scholar
  5. 5.
    Dobrovolskaia MA, McNeil SE (2007) Immunological properties of engineered nanomaterials. Nat Nanotechnol 2:469–478CrossRefGoogle Scholar
  6. 6.
    Comenge J, Romero FM, Sotelo C, Dominguez F, Puntes V (2010) Exploring the binding of Pt drugs to gold nanoparticles for controlled passive release of cisplatin. J Control Release 148:e31–32CrossRefGoogle Scholar
  7. 7.
    Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V (2010) Time evolution of the nanoparticle protein corona. ACS Nano 4:3623–3632CrossRefGoogle Scholar
  8. 8.
    Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S et al (2010) Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 31:6574–6581CrossRefGoogle Scholar
  9. 9.
    Love JC, Estroff LA, Kriebel JK, Nuzzo RG, Whitesides GM (2005) Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 105:1103–1170CrossRefGoogle Scholar
  10. 10.
    Simpson CA, Agrawal AC, Balinski A, Harkness KM, Cliffel DE (2011) Short-chain PEG mixed monolayer protected gold clusters increase clearance and red blood cell counts. ACS Nano 5:3577–3584CrossRefGoogle Scholar
  11. 11.
    Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci 105:17356–17361CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Joan Comenge
    • 1
  • Víctor F. Puntes
    • 1
  1. 1.Catalan Institute of NanotechnologyUniversitat Autònoma de BarcelonaBarcelonaSpain

Personalised recommendations